Vascular Dementia (VaD) is the second most common cause of dementia after Alzheimer's disease (AD), accounting for approximately 15-20% of all dementia cases globally. VaD results from cerebrovascular disease that impairs brain function through ischemic or hemorrhagic mechanisms, encompassing conditions ranging from multi-infarct dementia to subcortical vascular cognitive impairment. [@gorelick2011]
The mechanistic overlap between VaD and AD is substantial and increasingly recognized as clinically significant. Both conditions share key pathogenic pathways including blood-brain barrier (BBB) breakdown, chronic cerebral hypoperfusion, small vessel disease, white matter damage, and the deposition of amyloid in cerebral vessels. [@icloud2021] This convergence has led to the concept of "mixed dementia" — the coexistence of vascular and neurodegenerative pathology that together produce cognitive decline greater than either alone. [@rusanen2020] Understanding these shared mechanisms is critical for developing diagnostic biomarkers and therapeutic strategies that address both disease processes simultaneously.
Vascular Dementia (VaD) is the second most common cause of dementia after Alzheimer's disease (AD), accounting for approximately 15-20% of all dementia cases globally. VaD results from cerebrovascular disease that impairs brain function through ischemic or hemorrhagic mechanisms, encompassing conditions ranging from multi-infarct dementia to subcortical vascular cognitive impairment. [@gorelick2011]
The mechanistic overlap between VaD and AD is substantial and increasingly recognized as clinically significant. Both conditions share key pathogenic pathways including blood-brain barrier (BBB) breakdown, chronic cerebral hypoperfusion, small vessel disease, white matter damage, and the deposition of amyloid in cerebral vessels. [@icloud2021] This convergence has led to the concept of "mixed dementia" — the coexistence of vascular and neurodegenerative pathology that together produce cognitive decline greater than either alone. [@rusanen2020] Understanding these shared mechanisms is critical for developing diagnostic biomarkers and therapeutic strategies that address both disease processes simultaneously.
Cerebral small vessel disease (SVD) is the primary pathological substrate of VaD and contributes significantly to AD progression. SVD affects the small arteries, arterioles, capillaries, and venules of the brain, with arteriolosclerosis and lipohyalinosis being the most common findings in sporadic VaD. [@pantoni2023] These pathological changes narrow vessel lumens, reduce cerebral blood flow, and compromise the integrity of the neurovascular unit.
The MRI-visible manifestations of SVD include white matter hyperintensities (WMH), lacunes, microbleeds, enlarged perivascular spaces, and recent small subcortical infarcts. [@prins2022] White matter hyperintensities, detected on T2/FLAIR MRI as hyperintense regions in the deep and periventricular white matter, reflect tissue damage from chronic hypoperfusion, BBB leakage, and demyelination. The Fazekas scale grades WMH severity from 0 (none) to 3 (confluent), with higher grades correlating with greater cognitive impairment and faster decline. [@van_veluw2020]
The burden of WMH independently predicts cognitive decline, with each increment in Fazekas grade associated with measurably worse executive function and processing speed. [@prins2022] Beyond the direct effects of white matter damage, WMH reduces the brain's cognitive reserve by disconnecting frontal-subcortical circuits essential for attention, working memory, and behavioral regulation.
SVD is present in a substantial proportion of AD patients, with studies demonstrating that 30-60% of clinically diagnosed AD patients have moderate to severe white matter disease on MRI. [@hilal2019] This prevalence is considerably higher than age-matched cognitively normal controls, suggesting that vascular pathology accelerates or synergizes with AD pathology.
The apolipoprotein E ε4 (APOE4) allele — the strongest genetic risk factor for AD — also increases susceptibility to SVD. [@shi2019] APOE4 carriers show accelerated WMH progression compared to non-carriers, independent of amyloid burden, indicating that APOE4 affects vascular health through mechanisms beyond its role in Aβ metabolism. This finding supports the vascular hypothesis of AD, in which APOE4-mediated damage to the neurovascular unit drives cognitive decline through impaired clearance and perfusion. [@sweeney2019]
The synergistic effect of SVD and AD pathology is particularly striking. Studies using PET amyloid imaging combined with MRI have demonstrated that WMH and amyloid deposition have independent and additive effects on cognitive decline. [@ciarello2023] Patients with both high amyloid burden and high WMH burden show the fastest cognitive trajectory, indicating that the two pathological processes compound rather than simply add.
BBB dysfunction is a common feature of both VaD and AD, driven by overlapping molecular mechanisms. In SVD-related VaD, chronic hypertension induces lipohyalinosis of small arterioles, leading to vessel wall degeneration and increased permeability. [@kehoe2021] Matrix metalloproteinases (MMPs), particularly MMP-9, are upregulated in response to ischemic injury and degrade tight junction proteins including claudin-5, occludin, and ZO-1, compromising barrier integrity.
The consequence of BBB breakdown is extravasation of plasma proteins into brain parenchyma, including fibrinogen, albumin, and immunoglobulins. [@zhu2020] Fibrinogen extravasation deposits fibrin cross-linked into fibrin clots that persist in brain tissue, where it directly induces demyelination, axonal damage, and microglial activation. Research has identified fibrinogen as a key mediator linking vascular dysfunction to neurodegeneration, with fibrinogen deposition correlating with cognitive impairment severity in both VaD and AD. [@zhu2020]
Pericytes — the mural cells embedded in the capillary basement membrane — play a critical role in maintaining BBB integrity. Pericyte deficiency, documented in both VaD and AD post-mortem studies, leads to increased endothelial transcytosis, reduced tight junction coverage, and greater BBB permeability. [@sweeney2019] In AD, pericyte loss is driven in part by Aβ deposition and inflammatory cytokines; in VaD, chronic ischemia and hypertension contribute to pericyte degeneration.
Dynamic contrast-enhanced MRI (DCE-MRI) quantifies BBB permeability in vivo, enabling detection of barrier dysfunction before significant tissue damage occurs. [@zhu2020] Studies using DCE-MRI have demonstrated increased BBB permeability in the hippocampus and deep white matter of both VaD and AD patients, with permeability increasing as disease severity advances.
In VaD, BBB leakage is most prominent in subcortical white matter regions affected by SVD, reflecting the localized nature of small vessel pathology. [@kehoe2021] In AD, BBB breakdown is more diffuse but particularly evident in the hippocampus and entorhinal cortex — the regions most vulnerable to AD pathology. Notably, BBB permeability can be elevated in pre-symptomatic individuals decades before clinical disease onset, suggesting vascular dysfunction as an early initiator of the pathogenic cascade. [@icloud2021]
Cerebrospinal fluid (CSF) biomarkers complement imaging findings. Decreased CSF levels of claudin-5 and occludin indicate tight junction damage, while elevated CSF/serum albumin ratios reflect global BBB permeability. These markers are elevated in both VaD and AD patients compared to age-matched controls, with the highest values observed in patients with mixed pathology. [@kehoe2021]
Chronic cerebral hypoperfusion (CCH) is the central hemodynamic consequence of SVD and a major driver of cognitive decline in VaD. By definition, CCH refers to a sustained reduction in cerebral blood flow (CBF) below the threshold required for normal neuronal function, typically resulting from stenosis or occlusion of major cerebral arteries combined with impaired autoregulation in small vessels. [@duncombe2022]
In SVD, the progressive narrowing of small arterioles reduces perfusion pressure to downstream brain tissue. The resulting chronic hypoxia activates a cascade of harmful molecular events: upregulation of hypoxia-inducible factors (HIF-1α, HIF-2α), increased expression of vascular endothelial growth factor (VEGF), activation of inflammatory pathways, and induction of apoptotic cascades. [@duncombe2022]
The prefrontal cortex, hippocampus, and deep white matter are particularly vulnerable to CCH due to their watershed vascular territories and high metabolic demands. The hippocampus — critical for memory formation and consolidation — relies heavily on continuous perfusion, making it especially sensitive to reductions in blood flow. [@tsai2020] This vulnerability explains why memory impairment is prominent in both VaD and AD, even though the primary pathology differs.
Neurovascular coupling — the mechanism by which increased neuronal activity triggers a compensatory increase in local blood flow — is impaired in both conditions. [@icloud2021] This impairment means that when neurons are metabolically active, they cannot receive adequate oxygen and glucose delivery to meet demand, creating a functional hypoxia even at rest. Functional MRI studies demonstrate reduced cerebrovascular reactivity in both VaD and AD patients, with the degree of impairment correlating with cognitive performance. [@tsai2020]
CCH and AD pathology influence each other through multiple bidirectional pathways. [@duncombe2022] Hypoperfusion impairs Aβ clearance through the vasculature — LRP1-mediated efflux of Aβ from brain to blood requires adequate perfusion pressure — while simultaneously increasing Aβ production through activation of amyloidogenic processing of amyloid precursor protein (APP). Animal models of CCH demonstrate accelerated amyloid plaque formation and tau hyperphosphorylation, supporting the concept that vascular dysfunction can initiate or amplify AD pathology. [@duncombe2022]
Conversely, Aβ deposition in cerebral vessels (cerebral amyloid angiopathy, discussed below) worsens vascular dysfunction, creating a vicious cycle. Aβ disrupts endothelial cell function, reduces nitric oxide bioavailability, and promotes oxidative stress in the vasculature. [@charidimou2019] These effects further reduce CBF, perpetuating the hypoperfusion that drives additional amyloid and tau pathology.
The white matter is particularly sensitive to CCH because of its dependency on anterograde axonal transport and myelin maintenance, both of which are energy-intensive processes. Chronic hypoperfusion causes oligodendrocyte death, demyelination, and axonal degeneration in the deep white matter, producing the WMH visible on MRI. [@prins2022] This white matter damage disrupts the frontal-subcortical circuits necessary for executive function, producing the characteristic profile of subcortical VaD: impaired planning, reduced cognitive flexibility, slowed processing, and preserved episodic memory relative to cortical forms.
White matter hyperintensities (WMH) are focal or diffuse areas of T2/FLAIR signal hyperintensity in the white matter, representing a combination of demyelination, axonal loss, gliosis, and interstitial fluid accumulation. [@prins2022] They arise from two principal mechanisms: (1) chronic hypoperfusion of the deep white matter supplied by long penetrating arteries with limited collateral circulation, and (2) BBB dysfunction allowing plasma protein extravasation and inflammatory activation.
The spatial distribution of WMH follows vascular anatomy. Periventricular WMH, adjacent to the lateral ventricles, arise from disruption of the ventricular cerebrospinal fluid-contiguous pathway and impaired perfusion of the area nearest the ventricles. Deep WMH, in the centrum semiovale and deep white matter, reflect the chronic ischemia of the end-arterial territories of penetrating branches from the cortical arteries. [@van_veluw2020]
WMH severity progresses over time, with the rate of progression varying based on vascular risk factors, APOE status, and baseline amyloid burden. [@grimmer2022] Longitudinal studies using serial MRI demonstrate that WMH volume approximately doubles over 3-5 years in patients with established SVD, with progression correlating with declining cognitive performance.
The interaction between WMH and amyloid-β (Aβ) is synergistic rather than simply additive. [@ciarello2023] Patients with high WMH burden and high amyloid PET signal show faster cognitive decline than would be predicted by adding the effects of each pathology independently. This synergy has been attributed to several mechanisms:
Neuropathological studies confirm that AD patients with severe WMH have more extensive neurodegeneration than those with similar amyloid and tau burden but minimal WMH. [@rohr2021] This finding supports the clinical importance of targeting vascular pathology in AD, not only for VaD patients but for the broader population of AD patients with vascular comorbidity.
Cerebral amyloid angiopathy (CAA) involves the deposition of Aβ in the walls of leptomeningeal and cortical blood vessels, affecting an estimated 20-40% of cognitively normal elderly individuals and 50-80% of AD patients at autopsy. [@charidimou2019] The deposited Aβ replaces smooth muscle cells in the tunica media, weakens vessel walls, and increases the risk of lobar hemorrhages. In severe cases, vessel wall integrity is lost entirely, producing fibrinoid necrosis and microaneurysm formation.
CAA is diagnosed in vivo using the modified Boston criteria, which incorporate MRI findings: lobar macrohemorrhages, cortical superficial siderosis, convexity subarachnoid hemorrhage, and microbleeds in a lobar distribution. [@eriksen2023] The presence of multiple lobar microbleeds or disseminated cortical superficial siderosis is highly specific for moderate-to-severe CAA.
CAA directly connects vascular dementia and AD through the shared deposition of Aβ in different compartments — parenchymal plaques (AD) and vascular walls (CAA). Many patients have both, and the presence of CAA modifies the clinical phenotype and progression of AD. [@charidimou2019]
The vascular deposition of Aβ compromises the very vessels needed for Aβ clearance from the brain. This creates a self-reinforcing cycle: Aβ deposits in vessel walls → vessel function deteriorates → Aβ clearance decreases → more Aβ accumulates both in vessels and brain parenchyma. APOE4 carriers are particularly susceptible to this cycle due to the allele's role in both Aβ aggregation and perivascular clearance. [@shi2019]
From the VaD perspective, CAA contributes to cognitive decline through multiple mechanisms: (1) lobar hemorrhages that produce acute neurological deficits; (2) chronic hypoperfusion from vessel wall thickening and lumen narrowing; (3) BBB dysfunction from damaged vessels; and (4) secondary inflammatory response to vessel wall Aβ. [@eriksen2023] In pure VaD patients without AD pathology, CAA may represent the main link between vascular and amyloid pathways.
Treatment implications are significant. Drugs designed to reduce Aβ production or enhance clearance (e.g., monoclonal antibodies targeting Aβ) may benefit both parenchymal and vascular compartments, though the vascular risk of Aβ-targeting therapies (ARIA-E and ARIA-H) must be carefully managed in patients with CAA. [@eriksen2023]
Emerging therapeutic strategies address the vascular component of cognitive impairment. Blood pressure control remains the most evidence-based intervention — rigorous BP lowering with antihypertensive therapy significantly reduces stroke risk and slows WMH progression, with some studies demonstrating preserved cognitive function in treated hypertensive patients. [@smith2022] The SPRINT-MIND trial showed that intensive BP control reduced the development of mild cognitive impairment (MCI) and combined MCI/dementia, with the benefit attributed in part to reduced cerebrovascular damage.
Beyond blood pressure management, exercise, Mediterranean-style diet, and control of other vascular risk factors (diabetes, hypercholesterolemia, smoking) are recommended as they improve endothelial function, reduce inflammation, and slow WMH progression. [@iyare2023] These lifestyle interventions are particularly valuable for patients with mixed vascular and AD pathology, as they address both conditions simultaneously.
Novel vascular-targeted agents under investigation include: pericyte stabilizers (PDGF-BB analogues, S1P receptor modulators), BBB-protective compounds (MMP inhibitors, tight junction enhancers), and agents targeting fibrinogen-mediated neurotoxicity. [@iyare2023] The recognition that vascular dysfunction is an early and potentially initiating event in AD has shifted the therapeutic pipeline toward agents that protect or restore neurovascular function.
Management of mixed dementia requires addressing both vascular and neurodegenerative pathology. For patients with both SVD and AD pathology, treatment should include: (1) rigorous vascular risk factor control; (2) anti-amyloid therapy if amyloid burden is confirmed and CAA is not severe; (3) symptomatic treatments (cholinesterase inhibitors and memantine for AD symptoms); and (4) lifestyle modifications. [@rusanen2020] Accurate diagnosis of the relative contributions of each pathology is increasingly possible with combined MRI and PET amyloid/tau imaging, enabling more targeted therapeutic approaches.
| Feature | Vascular Dementia | Alzheimer's Disease | Mixed Dementia |
|---------|-------------------|---------------------|----------------|
| Primary Pathology | SVD, ischemic infarcts, WMH | Aβ plaques, tau tangles | Both |
| WMH Burden | Severe (Fazekas 2-3) | Variable (often moderate) | Severe |
| CAA Prevalence | 20-30% | 50-80% | 50-70% |
| BBB Permeability | Elevated (subcortical) | Elevated (hippocampus) | Diffusely elevated |
| Cerebral Blood Flow | Markedly reduced | Reduced (posterior) | Severely reduced |
| White Matter Integrity | Severely compromised | Moderately compromised | Severely compromised |
| Cognitive Profile | Executive greater than memory | Memory greater than executive | Mixed, often severe |
| Stroke Risk | High | Moderate | High |
| Key MRI Markers | Lacunes, WMH, microbleeds | Medial temporal atrophy | All of the above |